Sources and References

Primary textbook — Compendium of Therapeutics for Minor Ailments. Ottawa, ON: Canadian Pharmacists Association. [Available online: https://myrxtx.ca/search] Supplementary texts — Krinsky DL, Berardi RR, Ferrari SP, et al. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care. 21st ed. Washington, DC: American Pharmaceutical Association; 2024. — Herrier R, Apgar D, Boyce R, Foster S. Patient Assessment in Pharmacy. China: McGraw-Hill Education; 2015. Online resources — Health Canada natural health product database; Society of Obstetricians and Gynaecologists of Canada (SOGC) clinical practice guidelines; Infectious Diseases Society of America guidelines; Canadian Dermatology Association resources; CPS (Compendium of Pharmaceuticals and Specialties)

Chapter 1: Foundations of Advanced Minor Ailment Care

The Evolving Landscape of Self-Care in Canadian Pharmacy

Patient self-care — the practice of individuals managing their own health conditions with or without the assistance of a healthcare provider — has undergone a profound transformation in Canadian pharmacy practice over the past decade. What was once a relatively circumscribed domain of nonprescription product recommendations has expanded, through legislative and regulatory evolution, into a sophisticated clinical practice area in which pharmacists assess, diagnose, prescribe, and monitor patients presenting with a wide spectrum of minor ailments. Understanding this evolution is essential not only for appreciating the scope of what pharmacists may now do, but for recognizing the elevated clinical and ethical responsibilities that expansion entails.

The legislative milestone in Ontario was the expansion of pharmacist prescribing authority under the Drug and Pharmacies Regulation Act and the Regulated Health Professions Act amendments, which granted Ontario pharmacists the authority to prescribe for a defined list of minor ailments beginning in 2023. This placed Ontario in alignment with provinces such as British Columbia, Alberta, Saskatchewan, and Nova Scotia, which had implemented similar frameworks years earlier. The minor ailment list encompasses conditions including urinary tract infections (uncomplicated), allergic rhinitis, oral candidiasis, herpes labialis, insect bites, musculoskeletal sprains and strains, and skin conditions including dermatophytoses and impetigo, among others.

The Pharmacists’ Patient Care Process (PPCP) — Collect, Assess, Plan, Implement, Follow-up — is the organizing framework for all minor ailment encounters. Applied to self-care, this means systematically gathering a focused history (symptom onset, duration, character, aggravating and relieving factors, prior treatments, medications, allergies, and relevant medical history), assessing whether the presentation is consistent with a minor ailment manageable within pharmacist scope or requires referral, developing an evidence-based care plan with specific product recommendations and non-pharmacological measures, counselling the patient, and arranging appropriate follow-up to evaluate therapeutic response and detect complications.

Drug Schedule Classifications and Self-Care Products

The regulatory framework governing the sale of therapeutic products in Canada is built around a schedule classification system that determines the level of professional oversight required at the point of sale. Understanding this system is foundational to self-care practice.

Schedule I drugs require a valid prescription from an authorized prescriber and may only be dispensed by a pharmacist. Many of the drugs now accessible to patients through pharmacist minor ailment prescribing are Schedule I products — antibiotics for UTI, prescription antifungals, or antivirals — that require pharmacist assessment before they can be provided.

Schedule II drugs do not require a prescription but must be sold by a pharmacist or under pharmacist supervision and are stored behind the pharmacy counter. The patient must be assessed by the pharmacist before purchase. Schedule II products include several important self-care items including emergency contraception (Plan B), insulin, pseudoephedrine, and some ophthalmic products.

Schedule III drugs are sold only in a pharmacy setting and must be kept in the professional service area, but pharmacist counselling is not mandatorily required (though it is professionally expected). Antihistamines, topical corticosteroids, and many analgesics fall into this category.

Unscheduled drugs may be sold in any retail setting without professional oversight. They have a well-established safety profile that supports their use without mandatory pharmacist involvement.

Natural Health Products (NHPs) are governed in Canada by the Natural Health Products Regulations under the Food and Drugs Act. Unlike drugs, NHPs require a Natural Product Number (NPN) or Homeopathic Medicine Number (DIN-HM) that confirms Health Canada has reviewed the product’s evidence for safety, efficacy, and quality at the approved dose. However, the evidence standard for NHPs is generally lower than that for prescription drugs, and many NHPs carry uncertain or limited efficacy evidence for their indicated uses. Pharmacists must be equipped to critically evaluate NHP evidence and communicate the distinction between regulatory approval and clinical evidence of benefit to patients.

Chapter 2: Reproductive and Sexual Health

Emergency Contraception

Emergency contraception (EC) is a time-sensitive intervention that reduces the risk of pregnancy following unprotected or inadequately protected sexual intercourse. Its provision represents one of the most important Schedule II pharmacist clinical activities, requiring not only knowledge of the available methods and their mechanisms but the communication skills and non-judgmental professional approach to serve patients who may be experiencing distress or stigma.

The most commonly used form of EC in Canada is levonorgestrel 1.5 mg (Plan B), a progestogen-only oral preparation that must be taken as soon as possible after unprotected intercourse and is approved for use within 72 hours, with decreasing efficacy as time from intercourse increases. Its primary mechanism of action is inhibition of or delay in ovulation — the drug prevents the LH surge that triggers follicular rupture. If ovulation has already occurred, levonorgestrel is unlikely to prevent pregnancy, a nuance important for counselling patients who present after mid-cycle. Levonorgestrel EC does not interrupt an established pregnancy and is not an abortifacient. Its effectiveness (approximately 85% reduction in expected pregnancies when taken within 72 hours) is reduced by higher body weight; for individuals with a body weight above approximately 75 kg, ulipristal acetate 30 mg (EllaOne) may offer superior efficacy. Ulipristal acetate is a selective progesterone receptor modulator that inhibits or delays ovulation and is effective for up to 120 hours after intercourse.

The copper intrauterine device (IUD) is the most effective form of emergency contraception (>99% effective) when inserted within 5 to 7 days of unprotected intercourse. IUD insertion is not within community pharmacist scope of practice but represents an important referral option for appropriate patients, particularly those who desire ongoing contraception.

Pharmacist counselling for EC should address the mechanism and expected efficacy, the importance of timeliness, potential side effects (nausea, irregular menstrual bleeding), the limitation that EC does not protect against sexually transmitted infections, and the option of ongoing contraception after the next menstrual period. Contraindications to levonorgestrel EC are essentially none — even most drug interactions are clinically irrelevant given the single-dose, short-duration exposure. CYP3A4 inducers (rifampin, anticonvulsants, St. John’s Wort) may reduce levonorgestrel’s efficacy by accelerating its metabolism; in these patients, ulipristal acetate (also a CYP3A4 substrate, but potentially less affected) or a copper IUD should be recommended.

Pelvic Pain Assessment and Management

Pelvic pain encompasses a heterogeneous spectrum of conditions ranging from the predictable cyclical discomfort of primary dysmenorrhea to the complex, often diagnosis-delayed presentations of endometriosis, pelvic inflammatory disease, and ovarian pathology. Pharmacists’ role in pelvic pain is primarily one of triage — distinguishing presentations appropriate for self-care management from those requiring urgent or non-urgent medical referral — and of evidence-based management of primary dysmenorrhea, the most common minor ailment in this category.

Primary dysmenorrhea is menstrual pain in the absence of underlying pelvic pathology. It results from excessive endometrial prostaglandin synthesis — particularly prostaglandins F2α and E2 — during the secretory phase and menses, causing uterine hypercontractility, ischemia, and sensitization of pain receptors. The pharmacologic cornerstone of management is inhibition of prostaglandin synthesis through non-steroidal anti-inflammatory drugs (NSAIDs). Ibuprofen (400 to 600 mg every 4 to 6 hours, beginning 1 to 2 days before the expected onset of menses and continuing for the first 2 to 3 days) and naproxen sodium (550 mg initial dose followed by 275 to 550 mg every 6 to 8 hours) are the most evidence-supported agents. Starting NSAIDs before the onset of pain — when prostaglandin synthesis is already underway — is more effective than beginning treatment after cramping starts.

Secondary dysmenorrhea is pelvic pain attributable to underlying pathology. Endometriosis — the presence of endometrial-like tissue outside the uterus, most commonly on the ovaries, fallopian tubes, and pelvic peritoneum — causes dysmenorrhea, dyspareunia, and chronic pelvic pain and affects an estimated 10% of reproductive-age individuals. Diagnosis of endometriosis requires laparoscopic confirmation and is notoriously delayed, with an average diagnostic lag of 7 to 10 years from symptom onset. Pharmacists should maintain a high index of suspicion for secondary causes when dysmenorrhea is severe, begins after age 25, is progressive rather than improving over time, or is accompanied by dyspareunia, dyschezia, or infertility. These presentations warrant prompt medical referral.

Chapter 3: Peri-natal Nutrition and Self-Care

Nutrition During Pregnancy

Pregnancy imposes substantially increased nutritional demands on the developing organism and the gestational parent. A pharmacist advising patients on peri-natal nutrition must distinguish between nutrients for which supplementation is supported by strong evidence, those for which evidence is mixed or uncertain, and those for which supplementation offers no established benefit and may be harmful.

Folic acid supplementation is the most thoroughly evidenced nutritional intervention in reproductive health. Neural tube defects (NTDs) — including spina bifida and anencephaly — arise from failure of the neural tube to close properly in the fourth week of gestation, before many pregnancies are recognized. Because adequate folate status must be established before conception occurs, Health Canada recommends that all individuals capable of pregnancy consume 0.4 mg of folic acid daily from a multivitamin and through folate-rich foods; the recommended dose rises to 0.4 to 1.0 mg daily during pregnancy for those at average risk of NTD, and 4 mg daily beginning at least three months before conception for those at high risk (prior NTD-affected pregnancy, personal or family history of NTD, antiepileptic drug use, poorly controlled diabetes, or obesity). Canada’s policy of mandatory folic acid fortification of white flour, cornmeal, and pasta since 1998 has reduced NTD prevalence by approximately 46%, but supplementation remains essential because fortification alone is insufficient to reach recommended intake levels in all individuals.

Iron requirements increase substantially during pregnancy, particularly in the second and third trimesters, to support fetal iron stores, placental function, and the expansion of maternal red cell mass. Iron-deficiency anemia in pregnancy is associated with preterm birth, low birth weight, and impaired neonatal neurodevelopment. Canadian prenatal guidelines recommend universal supplementation with 16 to 20 mg of elemental iron daily for most pregnant individuals, with higher doses (up to 100 mg/day) for those with established iron-deficiency anemia. Iron absorption is enhanced by simultaneous vitamin C intake and inhibited by calcium, tea, and coffee; these interaction points are important counselling content.

Omega-3 long-chain polyunsaturated fatty acids — particularly docosahexaenoic acid (DHA) — are critical for fetal brain and retinal development during the third trimester. Most prenatal vitamins do not contain adequate DHA, and dietary intake from fatty fish may be insufficient or avoided due to concerns about mercury exposure. Health Canada recommends that pregnant individuals consume at least 150 g of cooked fish per week from low-mercury species and consider supplementation with 200 to 300 mg of DHA daily. Fish high in mercury — including shark, swordfish, fresh or frozen tuna, escolar, marlin, and orange roughy — should be limited or avoided during pregnancy due to the developmental neurotoxicity of methylmercury.

Vitamin D status during pregnancy influences fetal bone development, immune function, and potentially neurodevelopment and the risk of gestational diabetes and preeclampsia, though evidence for clinical benefit of supplementation beyond preventing deficiency is inconsistent. Health Canada recommends 600 IU of vitamin D daily during pregnancy; individuals who are vitamin D deficient, have limited sun exposure, have darkly pigmented skin, or are obese may require higher doses.

Breastfeeding Support

Breastfeeding provides nutritional, immunological, and developmental benefits for infants that are unmatched by any formula, and pharmacist support for breastfeeding includes both clinical guidance on common breastfeeding problems and evidence-based counselling on medication safety during lactation.

Common breastfeeding challenges that pharmacists may encounter include nipple pain and trauma (often caused by improper latch and amenable to positioning correction rather than pharmacotherapy), engorgement (treated with regular feeding, hand expression, and cold compresses), and mastitis (inflammation of breast tissue, which may be infectious or non-infectious and warrants antibiotic therapy with cloxacillin or cephalexin if signs of bacterial infection are present). Nipple creams containing purified lanolin are widely used and generally safe, though evidence for their superiority over expressed breast milk applied to the nipple is limited.

Drug transfer to breast milk depends on the physicochemical properties of the drug — specifically its molecular weight, lipophilicity, protein binding, and ionization at physiologic pH — and on maternal pharmacokinetics. The LactMed database (US National Library of Medicine) provides regularly updated, evidence-based information on specific drugs and their levels in breast milk, infant blood levels when measured, and potential infant adverse effects. For most medications, the amount transferred to a breastfed infant through milk is small — typically less than 1% to 2% of the maternal dose — and clinically insignificant. Drugs of particular concern include those with high oral bioavailability, small molecular weight enabling passive diffusion into milk, long half-life accumulating in milk, and known infant toxicity even at low levels.

Pinworm: Diagnosis and Treatment

Enterobiasis, caused by the intestinal nematode Enterobius vermicularis, is the most common helminthic infection in Canadian children and is highly transmissible within households and institutional settings. The female worm migrates from the cecum to the perianal skin at night to deposit her eggs, causing intense nocturnal pruritus ani that is the hallmark symptom. Diagnosis is confirmed by the tape test (Scotch tape applied to the perianal skin on waking, then examined microscopically for eggs), though empiric treatment is often clinically appropriate when the symptom pattern is classic.

Treatment of choice is mebendazole 100 mg as a single oral dose, repeated after two weeks to eliminate worms that hatched from eggs after the initial treatment. The two-week interval corresponds to the developmental period of the worm from egg to reproductive adult. Pyrantel pamoate (alternative available in Canada) works as a neuromuscular blocking agent in nematodes, causing spastic paralysis. Because reinfection is common and household transmission is likely, simultaneous treatment of all household members — regardless of symptom presence — is recommended. Strict hygiene measures — handwashing, daily bathing, washing bedding in hot water, and cutting fingernails short to eliminate the egg reservoir — are essential complements to pharmacotherapy.

Chapter 4: Dermatology in the Self-Care Setting

Seborrheic Dermatitis

Seborrheic dermatitis is a chronic, recurrent inflammatory skin condition affecting the sebaceous gland-rich areas of the body — principally the scalp, face (nasolabial folds, eyebrows, beard area), and presternal region. It affects approximately 3% to 5% of the general population and up to 83% of individuals with HIV, where its severity often correlates with degree of immunosuppression. The condition is associated with — though not caused by — the lipophilic yeast Malassezia species, which colonize sebaceous areas and are hypothesized to trigger an aberrant inflammatory response in predisposed individuals.

On the scalp, seborrheic dermatitis manifests as the common dandruff (pityriasis capitis) at its mildest, presenting as dry, white-gray scaling without erythema. More severe forms produce yellow, greasy scales with underlying erythema and pruritus. On the face, erythematous, scaly patches follow the distribution of the nasolabial folds, glabella, and medial eyebrows, and may be difficult to distinguish from rosacea or psoriasis without careful clinical assessment.

Self-care management centres on medicated shampoos and topical antifungals. Zinc pyrithione (available in Head & Shoulders and other antidandruff shampoos) reduces Malassezia load through its antifungal and antibacterial activity and is appropriate as first-line therapy for mild scalp seborrheic dermatitis. Selenium sulfide 1% shampoos (Selsun Blue) similarly reduce yeast colonization. Ketoconazole 1% shampoo (Nizoral A-D), available without prescription in Canada, has the strongest antifungal activity and is particularly effective for moderate disease; clinical trial evidence supports its superiority over placebo and comparability to prescription-strength preparations. For facial seborrheic dermatitis, low-potency topical corticosteroids (hydrocortisone 0.5% to 1%) provide rapid symptomatic relief and are appropriate for short-term use, while ketoconazole 2% cream (prescription) addresses the underlying yeast component. Patients should understand that seborrheic dermatitis is a chronic, relapsing condition — treatment suppresses but does not cure it, and maintenance therapy is often required.

Dermatologic Assessment in Skin of Colour

The assessment and description of dermatologic conditions has been systematically biased toward presentation in lighter skin tones, a bias encoded in medical education materials, dermatology textbooks, and clinical training for generations. This has concrete consequences: conditions may be missed, misdiagnosed, or under-treated in patients with darker skin tones because clinicians trained on Eurocentric reference standards fail to recognize how the same condition presents differently across the Fitzpatrick skin phototype spectrum.

Erythema — redness — is the most commonly taught marker of skin inflammation. In patients with deeply pigmented skin, erythema may be nearly invisible or present as a subtle violet or grey discolouration rather than the pink-red easily recognized in lighter skin. Pharmacists and clinicians must develop the skill of assessing inflammation through alternative markers: warmth and texture changes (scale, induration, papule formation), patient-reported symptoms (pruritus, burning, pain), and careful inspection under good lighting. Hyperpigmentation following resolution of inflammatory skin conditions — post-inflammatory hyperpigmentation (PIH) — is far more prominent and often more distressing to patients with darker skin tones than in those with lighter skin, and is a clinically important consideration when counselling patients about treatment expectations and timeline.

Cutaneous Candidiasis and Dermatophytosis

Fungal infections of the skin are among the most common dermatologic conditions managed in the community pharmacy setting. They encompass two distinct groups of organisms — the yeasts (principally Candida species) and the dermatophytes (Trichophyton, Microsporum, and Epidermophyton genera) — which cause overlapping but characteristically different clinical presentations and require distinct treatment approaches.

Cutaneous candidiasis occurs in warm, moist skin folds — the inframammary region, inguinal folds, interdigital spaces, perianal skin, and under abdominal skin folds in obese individuals — where Candida albicans can transition from commensal to pathogen in the setting of local moisture, maceration, or systemic predisposing factors (diabetes mellitus, immunosuppression, broad-spectrum antibiotic use). The classic presentation is a beefy-red, macerated plaque with satellite pustules beyond the plaque border — the satellite lesions are a highly characteristic feature that distinguishes candidiasis from intertrigo of other causes. First-line nonprescription treatment is a topical azole antifungal — clotrimazole 1% or miconazole 2% cream — applied twice daily for 2 to 4 weeks. Keeping the affected area dry and allowing air circulation are essential adjunctive measures; moisture-wicking powders (avoiding cornstarch, which serves as a nutrient for Candida) may be helpful.

Dermatophytosis encompasses a family of conditions named by body site: tinea pedis (athlete’s foot), tinea cruris (jock itch), tinea corporis (ringworm of the body), tinea capitis (ringworm of the scalp), and onychomycosis (fungal nail infection). Dermatophytes are obligate keratin-digesting fungi that colonize the stratum corneum, hair, and nails, producing the characteristic annular, scaling, pruritic plaques of tinea corporis and the macerated, scaling, pruritic toe web spaces of tinea pedis. Tinea pedis is classified into three morphological patterns: the interdigital type (most common, affecting web spaces), the moccasin type (hyperkeratotic scaling of the sole and lateral foot), and the vesiculobullous type (inflammatory blisters on the instep and sole).

Topical azoles and terbinafine are the primary treatments for uncomplicated tinea pedis, cruris, and corporis. Terbinafine 1% cream or spray (Lamisil) has fungicidal activity against dermatophytes (in contrast to the fungistatic activity of azoles) and achieves cure rates of 80% to 90% with 1-week courses for interdigital tinea pedis — a significant advantage over the 2 to 4 weeks required with clotrimazole or miconazole. Onychomycosis is generally not amenable to topical therapy because antifungals cannot penetrate the nail plate to therapeutic concentrations; systemic therapy with oral terbinafine (250 mg daily for 6 weeks for fingernails, 12 weeks for toenails) is required for confirmed onychomycosis, but nail clippings should be sent for culture to confirm dermatophyte infection before initiating systemic antifungal therapy, as nail dystrophy has many non-fungal causes. Tinea capitis likewise requires systemic therapy — typically oral griseofulvin or terbinafine — because topical antifungals cannot eradicate scalp ringworm; most cases of tinea capitis occur in children and require appropriate dose adjustment.

Chapter 5: Gastrointestinal Health

Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent abdominal pain associated with a change in bowel habit, in the absence of structural, biochemical, or microbiological abnormality to account for symptoms. It is one of the most common chronic gastrointestinal conditions in Canada, affecting an estimated 13% to 20% of the population, with a female-to-male predominance of approximately 2:1. IBS represents a significant quality of life burden and a frequent source of self-care inquiries in community pharmacy.

The Rome IV diagnostic criteria define IBS by the presence of recurrent abdominal pain occurring at least 1 day per week on average during the preceding 3 months, associated with 2 or more of the following: relation to defecation; change in stool frequency; change in stool form (appearance). IBS is further subtyped based on the predominant bowel habit: IBS-C (constipation-predominant), IBS-D (diarrhea-predominant), IBS-M (mixed), and IBS-U (unclassified). Pharmacist assessment of suspected IBS must screen for “red flag” features that warrant medical referral rather than self-care management: age of symptom onset over 50 years, rectal bleeding, nocturnal symptoms awakening the patient from sleep, unintentional weight loss, progressive dysphagia, or family history of colorectal cancer or inflammatory bowel disease.

Non-pharmacological management is foundational in IBS and should be discussed thoroughly before or alongside any pharmacotherapy. A low FODMAP diet — restricting fermentable oligosaccharides, disaccharides, monosaccharides, and polyols that are osmotically active in the intestinal lumen and rapidly fermented by colonic bacteria to produce gas — reduces IBS symptoms in approximately 50% to 70% of patients in clinical trials. However, the diet is complex, restrictive, and should ideally be implemented with dietitian guidance to ensure nutritional adequacy. Soluble fiber supplementation (psyllium) reduces global IBS symptoms, particularly in IBS-C; insoluble fiber (wheat bran) may worsen bloating and should generally be avoided. Peppermint oil enteric-coated capsules — available as a nonprescription product in Canada — act as calcium channel antagonists in intestinal smooth muscle, reducing spasm, and have demonstrated efficacy over placebo in multiple RCTs for global IBS symptom relief.

For IBS-C, osmotic laxatives such as polyethylene glycol (PEG, Miralax, Lax-A-Day) increase intraluminal water, improve stool consistency, and reduce straining; they are generally preferred over stimulant laxatives for the regular management of constipation in IBS. For IBS-D, loperamide — a peripheral opioid receptor agonist that slows intestinal motility without CNS effects — reduces stool frequency and urgency but does not improve abdominal pain or global IBS symptoms and is most appropriately used for situational management of diarrhea rather than as primary IBS therapy.

Laxative Use and Abuse

The pharmacology and clinical pharmacology of laxatives is an important self-care topic because these products are extensively used (and frequently misused) in the community setting. Laxatives are classified by mechanism of action into four main groups.

Osmotic laxatives — including polyethylene glycol, lactulose, magnesium hydroxide, and sodium phosphate — draw water into the intestinal lumen osmotically, increasing intraluminal fluid and promoting peristalsis. PEG is the best-tolerated and most evidence-supported osmotic laxative for chronic constipation and is safe for long-term use. Lactulose is metabolized by colonic bacteria to short-chain fatty acids that acidify the colonic lumen, and while effective, it produces more bloating and flatulence than PEG. Magnesium-containing laxatives should be used with caution in patients with renal impairment, as magnesium accumulation can cause hypermagnesemia.

Stimulant laxatives — including senna (Senokot) and bisacodyl (Dulcolax) — act on enteric nerves and epithelial cells to stimulate secretion and peristalsis. They produce reliable bowel movements within 6 to 12 hours (oral bisacodyl) or 15 to 60 minutes (bisacodyl suppositories). The long-held concern that stimulant laxative use causes “cathartic colon” — permanent damage to colonic neurons — is not supported by current evidence; these agents are now considered appropriate for long-term use in chronic constipation when osmotic agents are insufficient.

Bulk-forming laxatives — psyllium, methylcellulose — work by absorbing water to form a gel that increases stool bulk and promotes peristalsis. They require adequate fluid intake to be effective and may worsen symptoms in patients with slow colonic transit who cannot tolerate the increased luminal bulk.

Emollient/softening laxatives — docusate sodium — lower stool surface tension, allowing water and fat to penetrate the fecal mass. Their efficacy for established constipation is limited, and evidence for docusate’s superiority over placebo in clinical trials is modest.

Chapter 6: Infectious Disease Minor Ailment Prescribing

Uncomplicated Urinary Tract Infections

Uncomplicated urinary tract infection (UTI) is one of the most frequent minor ailment prescribing indications for pharmacists. In non-pregnant, immunocompetent, pre-menopausal females without anatomical abnormality or recent urologic instrumentation, the clinical diagnosis of uncomplicated cystitis — lower UTI — can be made on clinical grounds with high accuracy when the classic symptom triad of dysuria, urinary frequency, and urinary urgency is present in the absence of vaginal discharge or irritation.

The most common causative organism is Escherichia coli (accounting for approximately 80% to 85% of uncomplicated UTIs), followed by Staphylococcus saprophyticus (particularly in young sexually active women), Klebsiella pneumoniae, Proteus mirabilis, and Enterococcus faecalis. Local antimicrobial resistance patterns should inform empiric antibiotic choice.

Nitrofurantoin (100 mg modified-release capsule twice daily for 5 days, or 50 mg four times daily for 7 days) is first-line therapy for uncomplicated UTI in most Canadian guidelines, with excellent activity against the common uropathogens (except Proteus and Pseudomonas), low systemic bioavailability minimizing collateral effects on the gut microbiome, and low rates of resistance among E. coli. It should be avoided in patients with significant renal impairment (eGFR < 30 mL/min) because it will not achieve adequate urinary concentrations and may accumulate to produce systemic toxicity.

Trimethoprim-sulfamethoxazole (TMP-SMX, 160/800 mg twice daily for 3 days) is an alternative when local E. coli resistance rates are below 20%; in many Canadian regions, resistance rates now exceed this threshold, limiting its empiric use.

Fosfomycin trometamol (3 g sachet, single dose) is an alternative approved in Canada with excellent activity against E. coli and Enterococcus faecalis, particularly useful for patients who cannot tolerate nitrofurantoin or TMP-SMX. Phenazopyridine, a urinary analgesic that turns urine orange-red, may be used for up to 2 days for symptomatic relief of dysuria while antibiotic therapy begins working, but patients must be counselled that it does not have antimicrobial activity.

Situations that fall outside uncomplicated UTI and require medical referral include: upper urinary tract symptoms (flank pain, fever, rigors, costovertebral angle tenderness suggesting pyelonephritis), pregnancy, male sex, structural or functional urinary abnormalities, diabetes mellitus, symptoms lasting more than 7 days, three or more UTIs in 12 months, or failure to respond to an adequate course of treatment.

Acute Pharyngitis

Most episodes of acute pharyngitis are viral in etiology and self-limiting within 7 to 10 days. The principal clinical concern is identifying the subset caused by group A Streptococcus (Streptococcus pyogenes) that warrants antibiotic therapy to prevent suppurative complications (peritonsillar abscess, otitis media, sinusitis) and, importantly, non-suppurative complications including acute rheumatic fever and post-streptococcal glomerulonephritis.

The Centor criteria (modified by McIsaac for the Canadian context) provide a validated clinical prediction rule for estimating the probability of GAS pharyngitis: tonsillar exudate (+1), tender anterior cervical lymphadenopathy (+1), fever or history of fever (+1), absence of cough (+1), and age modification (13 to 34 years: 0; ≥45 years: −1). A score of 0 to 1 indicates very low probability of GAS (< 10%) and no testing or antibiotic treatment is recommended. A score of 2 to 3 warrants rapid antigen detection testing or throat culture to guide therapy. A score of 4 or higher indicates high probability (> 50%) and empiric antibiotic therapy may be considered, though testing before treatment is generally preferred given the clinical consequences of unnecessary antibiotic prescribing.

First-line treatment for confirmed GAS pharyngitis is amoxicillin 500 mg twice daily for 10 days (or penicillin V 500 mg three times daily for 10 days). For penicillin-allergic patients (non-anaphylactic), a first-generation cephalosporin such as cephalexin 500 mg four times daily for 10 days is appropriate. For patients with history of anaphylactic penicillin allergy, azithromycin 500 mg daily for 5 days is used, though macrolide resistance rates among GAS are increasing.

Herpes Zoster (Shingles) Minor Ailment Prescribing

Herpes zoster results from reactivation of varicella-zoster virus (VZV) that has remained latent in dorsal root and cranial nerve ganglia following primary varicella (chickenpox) infection. Reactivation typically occurs when cell-mediated immunity to VZV wanes — whether through aging, immunosuppression, stress, or other factors — allowing the virus to replicate, travel down the sensory nerve, and produce the characteristic dermatomal vesicular eruption. The lifetime risk of zoster is approximately 30%, with risk increasing substantially after age 50 and in the immunocompromised.

The prodrome of herpes zoster — 1 to 5 days of dermatomal pain, tingling, or hyperesthesia before any rash appears — can be diagnostically challenging, as the pain may be mistaken for pleurisy, cardiac disease, or other conditions before the rash clarifies the diagnosis. The rash erupts as erythematous macules and papules that rapidly evolve into clusters of clear vesicles, becoming pustular over 3 to 5 days before crusting and resolving over 2 to 4 weeks. The distribution is strictly unilateral and dermatomal; bilateral or non-dermatomal eruptions should prompt reconsideration of the diagnosis.

Antiviral therapy with valacyclovir 1000 mg three times daily for 7 days or famciclovir 500 mg three times daily for 7 days is recommended within 72 hours of rash onset (or at any time while new lesions are appearing) for individuals over 50 years of age, immunocompromised patients, those with ophthalmic involvement, and those with moderate to severe pain or rash. Early antiviral therapy reduces viral replication, accelerates rash resolution, and — most importantly — reduces the incidence and duration of post-herpetic neuralgia (PHN), the most feared complication of zoster, characterized by persistent neuropathic pain in the affected dermatome lasting more than 90 days after rash onset. PHN affects 10% to 15% of all herpes zoster patients and up to 30% to 40% of those over 60, can persist for months to years, and is often refractory to treatment.

The recombinant zoster vaccine Shingrix (RZV), a two-dose adjuvanted subunit vaccine, has revolutionized zoster prevention, demonstrating approximately 97% efficacy in preventing zoster in adults aged 50 and older and approximately 91% efficacy in immunocompromised individuals. It is vastly superior to the older live attenuated zoster vaccine (Zostavax), which is no longer recommended by Canadian immunization authorities. Pharmacists are authorized to administer Shingrix and should actively identify and counsel eligible patients.

Chapter 7: Special Populations in Self-Care

Nonprescription Drug Use in Frail Individuals

Frailty is a clinical syndrome of decreased physiologic reserve and resistance to stressors, resulting from cumulative decline across multiple physiologic systems. The most widely used clinical frailty tools include the Fried frailty phenotype (assessing unintentional weight loss, exhaustion, low physical activity, slow gait speed, and weak grip strength, with frailty defined as 3 or more criteria) and the Clinical Frailty Scale (a 9-point ordinal scale from “very fit” to “terminally ill”). Frailty is distinct from disability or comorbidity, though it frequently co-occurs with both.

Frail individuals present particular challenges in the self-care context because the physiologic changes of frailty amplify the risks of both medications and illnesses. Pharmacokinetic changes — reduced renal clearance (diminished GFR from nephron loss and reduced renal blood flow), reduced hepatic metabolic capacity (lower liver mass and blood flow), decreased albumin concentrations (reduced protein binding for acidic drugs), and altered body composition (reduced lean mass and total body water, increased fat mass) — collectively raise drug concentrations and prolong drug exposure in frail older adults compared with younger adults receiving the same dose.

Pharmacodynamic sensitivity to many drug classes is also heightened in frail individuals. The CNS effects of antihistamines, benzodiazepines, opioids, and drugs with anticholinergic activity are amplified, increasing the risk of sedation, confusion, falls, and aspiration. The Beers Criteria (American Geriatrics Society) and the Canadian equivalent STOPP/START (Screening Tool of Older Persons’ Prescriptions/Screening Tool to Alert to Right Treatment) identify medications and medication classes that are potentially inappropriate in older adults, including many commonly used nonprescription products.

First-generation antihistamines (diphenhydramine, chlorpheniramine) — present in many OTC sleep aids, cold and flu preparations, and allergy products — cross the blood-brain barrier readily and produce profound anticholinergic effects in frail older adults: confusion, urinary retention, constipation, dry mucous membranes, and impaired balance. They are included on the Beers Criteria as drugs to be avoided in older adults. Pharmacists performing self-care consultations with frail patients should systematically screen for anticholinergic and sedating nonprescription products, recommend non-pharmacological alternatives where available, and propose age-appropriate substitutes where pharmacotherapy is warranted.

OTC Drugs of Abuse and Misuse Potential

Not all patients seeking nonprescription products do so for therapeutic purposes. Several categories of OTC drugs carry recognized abuse or misuse potential, and pharmacists occupy a critical gatekeeping position in identifying patterns of use that may indicate substance misuse and responding with appropriate clinical intervention.

Dextromethorphan (DXM) — present in many OTC cough preparations — is an N-methyl-D-aspartate (NMDA) receptor antagonist and sigma opioid receptor agonist that produces dissociative hallucinogenic effects at doses far above the therapeutic antitussive range. At recreational doses (typically 250 to 1500 mg, compared to the therapeutic 15 to 30 mg per dose), DXM produces effects described as “robo-tripping,” including euphoria, altered perception, hallucinations, and in severe cases, serotonin syndrome when combined with serotonergic medications, tachycardia, hyperthermia, and respiratory depression. Pharmacists should be alert to frequent purchasing of large quantities of DXM-containing products, particularly by adolescents, and apply provincial pseudoephedrine-tracking analogies of professional judgment to restrict sales to individuals showing signs of misuse.

Pseudoephedrine is a nasal decongestant sympathomimetic that is regulated under provincial pharmacy practice standards because of its role as a precursor in illicit methamphetamine synthesis. Ontario pharmacists are required to record all pseudoephedrine sales and refuse sales to individuals showing patterns consistent with diversion. Pharmacists should educate patients on appropriate therapeutic use and the availability of oxymetazoline nasal spray as a topical alternative that avoids systemic sympathomimetic effects for short-term nasal congestion management.

Laxative abuse in the context of eating disorders represents a particularly sensitive self-care challenge. Individuals with anorexia nervosa, bulimia nervosa, or other eating disorders may misuse stimulant laxatives in the (mistaken) belief that they promote weight loss; in reality, laxatives act on the large intestine after caloric absorption in the small intestine is largely complete, and their primary effect is water loss rather than caloric loss. Chronic stimulant laxative misuse causes electrolyte imbalances (hypokalemia, hyponatremia), colonic dysmotility, and dependency. Pharmacists who identify potential laxative misuse should respond with empathy, non-judgmental counselling, and referral to appropriate support services.